Kiplinger Kiplinger
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

From $107.88 $24.99

Subscribe to Kiplinger

  • Retirement Retirement
      • Retirement
        • View all Retirement
        • Annuities
        • Estate Planning
        • Retirement Plans
        • Social Security
        • Medicare
  • Investing Investing
      • Investing
        • View all Investing
        • Stocks
        • ETFs
        • Mutual Funds
        • Bonds
        • Wealth Management
        • AI
  • Taxes Taxes
      • Taxes
        • View all Taxes
        • Tax Returns
        • Tax Deductions
        • Capital Gains Taxes
        • State Taxes
        • Tax Planning
  • Personal Finance Personal Finance
      • Personal Finance
        • View all Personal Finance
        • Savings
        • Shopping and Deals
        • Credit Cards
        • Insurance
        • Money-saving
        • Banking
  • Life Life
      • Life
        • View all Life
        • Places to Live
        • Real Estate
        • Travel
        • Careers
        • Politics
        • Business
  • Adviser Intel
  • More
    • Kiplinger Puzzles
    • Quizzes
    • Tools and Calculators
    • Kiplinger Economic Forecasts
  • Newsletters
    • Newsletter sign-up
    • Manage my newsletters
    • Latest issue of Kiplinger Today
    • Latest issue of Closing Bell
  • Subscriptions
    • Subscriptions Store
    • My Subscriptions
    • Subscriptions Help
    • Kiplinger Personal Finance
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger Investing for Income
    • Kiplinger Retirement Report
    • Kiplinger Retirement Planning
  • Newsletter sign up Newsletter
  • Trending
    • Three Popular Tax Breaks Are Gone for Good in 2026
    • Five Retirement Planning Traps You Can't Afford
    • Qualified Dividends vs Ordinary Dividends
    • Don't Believe These Five Myths About Annuities

    When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

    Gilead Sciences (GILD)

    Latest

    null

    Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot

    Markets Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.

    Markets
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success

      investing Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      How to Survive the Economic Fallout from COVID-19

      investing The bull market and economic expansion are over. Here's what to do now.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      5 Undervalued Stocks With Free Cash Flow to Burn

      stocks Look beyond the P/E. These five firms are inexpensive based on free cash flow.

      stocks
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Why I'm Hanging On to a Loser

      investing Gilead is way down from when I bought it, but it is flush with cash and has dozens of promising medications in its pipeline.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Can This Fallen Biotech Be Revived?

      investing I've been sorely tempted to sell my Gilead shares. But now that they're cheaper, maybe I should buy more.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      This Stumbling Biotech Stock Still Has a Lot of Promise

      investing Gilead Sciences' robust product pipeline should turn things around.

      investing
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      3 Bargain Stocks to Beat the Market

      stocks The Value Line Investment Survey sees a strong year ahead for these picks.

      stocks
    • A person sitting at a desk, holding a pen, with a calculator, piggy bank and a stack of coins

      Promising Bargains in Biotech Stocks

      investing What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.

      investing
    1 2
    Kiplinger Logo
    • About Us
    • Contact Future's experts
    • Terms and Conditions
    • Privacy Policy
    • Cookie Policy
    • Advertise with us

    Kiplinger is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site.

    © Future US, Inc. Full 7th Floor, 130 West 42nd Street, New York, NY 10036.